Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verastem

5.67
+0.07001.25%
Volume:447.06K
Turnover:2.52M
Market Cap:311.56M
PE:-1.62
High:5.70
Open:5.64
Low:5.48
Close:5.60
Loading ...

Traders Cautious as 2024 Draws to Close, Stifling US Equity Futures Pre-Bell

MT Newswires Live
·
31 Dec 2024

Morning Movers: EHang jumps following guidance raise

TIPRANKS
·
31 Dec 2024

Verastem Shares up 27.5% Premarket After FDA Grants Priority Review for Ovarian Cancer Combo Therapy

THOMSON REUTERS
·
31 Dec 2024

Top Premarket Gainers

MT Newswires Live
·
31 Dec 2024

BUZZ-Verastem jumps as FDA grants priority review for ovarian cancer combo therapy

Reuters
·
31 Dec 2024

BTIG Raises Price Target on Verastem to $20 From $13, Keeps Buy Rating

MT Newswires Live
·
31 Dec 2024

Verastem price target raised to $20 from $13 at BTIG

TIPRANKS
·
31 Dec 2024

U.S. RESEARCH ROUNDUP- Axsome Therapeutics, Ducommun, Vacasa

Reuters
·
31 Dec 2024

Verastem Inc : Btig Raises Target Price to $20 From $13

THOMSON REUTERS
·
31 Dec 2024

Verastem Oncology's New Cancer Treatment Gets FDA Priority Review

Dow Jones
·
31 Dec 2024

Verastem's Ovarian Cancer Drug Application Accepted by FDA, Gets Priority Review

MT Newswires Live
·
31 Dec 2024

BRIEF-Verastem Oncology Announces FDA Acceptance And Priority Review Of New Drug Application For Avutometinib In Combination With Defactinib For The Treatment Of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer

Reuters
·
31 Dec 2024

Verastem announces FDA acceptance and Priority Review of NDA for Avutometinib

TIPRANKS
·
31 Dec 2024

Verastem jumps 50% to $5.50 on FDA priority review for Avutometinib

TIPRANKS
·
31 Dec 2024

Verastem Inc - Pdufa Target Action Date Set for June 30, 2025

THOMSON REUTERS
·
31 Dec 2024

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination With Defactinib for the Treatment of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer

THOMSON REUTERS
·
31 Dec 2024

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Business Wire
·
31 Dec 2024

Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS), Healthcare Services (HCSG) and Verastem (VSTM)

TIPRANKS
·
21 Dec 2024

Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)

TIPRANKS
·
21 Dec 2024

BRIEF-Applied Therapeutics Appoints John H. Johnson As Executive Chairman

Reuters
·
20 Dec 2024